News / Health

Ebola Emergency Turns Spotlight on Experimental Drugs

Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
Reuters

With hundreds of patients in Africa suffering the devastating effects of Ebola, health experts are scrambling to determine which drugs might offer the best experimental treatment, and researchers are being pressed by government officials to speed up their work.

Three treatments have shown especially promising results in monkeys, the researchers said. One, produced by tiny California biotech Mapp Biopharmaceutical, gained international prominence this week when it was given to two U.S. aid workers who contracted Ebola in West Africa and have since shown signs of improvement.

Others are from Vancouver-based Tekmira Pharmaceuticals and privately-held Profectus BioSciences, of Tarrytown, NY.

Click to enlargeClick to enlarge
x
Click to enlarge
Click to enlarge

On Wednesday the World Health Organization said it would discuss next week the ethics of using Ebola drugs that have never been cleared for human use, wary of a long history of medicines being tested on people who were never properly informed of the risks. In the countries hardest hit by Ebola, suspicion of foreign medical workers is already widespread.

But the health minister of Nigeria, Onyenbuchi Chukwu, told reporters this week that he had asked U.S. health officials about access to experimental Ebola therapies. U.S. drugmakers are fielding questions from government officials about their ability to supply treatments in sufficient quantities should the request come.

"For years we've told the government you need to invest a little bit of money in this," said Profectus chief scientific officer John Eldridge. "And now it's, 'Oh my God, how fast can you make this?' "

Officials at Mapp and Tekmira would not comment on efforts to make their treatments available in response to the outbreak.

President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
x
President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.

Speaking at a news conference on Wednesday, President Barack Obama said he lacks enough information to green-light Mapp's drug to treat the deadly Ebola virus and that the initial response should focus on public health measures to contain the outbreak.

"We've got to let the science guide us, and I don't think all the information is in on whether this drug is helpful," the president said, adding that public health officials, in the course of containing the current outbreak, could assess whether new drugs or treatments can be effective.

"We're focusing on the public health approach right now, but I will continue to seek information about what we're learning about these drugs going forward," he said.

Dr. James Crowe, director of the Vaccine Center at Vanderbilt University who has been developing an Ebola treatment similar to Mapp's, said a Pentagon agency contacted him this week about his work and added he will meet next week with government scientists about accelerating his research.

Monkey tests

No Ebola drugs or vaccines have even entered mid-stage human trials, let alone been approved. The furthest along have been tested only in monkeys and a handful of humans.

Mapp Biopharmaceutical began developing its ZMapp treatment more than a decade ago. It consists of a cocktail of nonoclonal antibodies, proteins that are highly specific for the Ebola virus and that are produced in bioengineered tobacco plants.

In 2012 Mapp, working with scientists at the U.S. Army Military Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland, announced that when rhesus macaques received the cocktail an hour after infection by Ebola, all survived. When they received it 48 hours after infection, two-thirds survived.

Last year, ZMapp passed a stiffer test: monkeys that had been infected with Ebola and developed fevers and other symptoms received the intravenous cocktail 104 to 120 hours after infection; 43 percent recovered.

When the U.S. government decided to develop a contingency plan in case of accidental exposure to Ebola by one or two people at a U.S. research facility, it began storing a small amount of ZMapp, according to a source familiar with the contingency plan. ZMapp was chosen because the science is relatively easy to understand and the risks considered relatively small, the source said.

The stock of Tekmira soared on expectations its Ebola drug might speed toward approval due to the crisis, or even be used in the current outbreak.

Under a $140 million contract with the U.S. Department of Defense, it is developing a drug based on a genetic technology called RNA interference.

The idea is to take strands of genetic material that are the virus's mirror image and, using nanoparticles, slip them into cells where Ebola is replicating. In theory, the RNA disables the virus.

In experiments by scientists at the army research unit, Tekmira reported last November, most animals infected with lethal amounts of Ebola survived when given the RNA product. The survival rate was 83 percent when the animals were treated 24 or 48 hours after infection and 67 percent when they were treated 72 hours after.

"It is amazing how well that works in non-human primates," said Ebola researcher Thomas Geisbert of the University of Texas Medical Branch, who has conducted several studies of the company's drug in monkeys.

Human trials

Last month, Tekmira announced that its early-stage human trial had been put on hold by the U.S. Food and Drug Administration, which had concerns about the drug's safety.

Tekmira declined requests for an interview.

Profectus BioSciences has also tested its Ebola vaccine in monkeys, with good results, said Eldridge.

In a study with scientists at government biomedical research centers and the Pentagon, Profectus found that a single intramuscular injection protected all of the rhesus monkeys exposed to Ebola three weeks later. The company hopes to launch a human trial to assess the vaccine's safety within the next 12 months, Eldridge said.

An experimental vaccine similar to Profectus's, developed by academic and government scientists, was rushed into emergency use only once. In 2009 a scientist in Germany working with Ebola-infected guinea pigs pricked her finger with a syringe containing the virus. The vaccine was flown from Canada, one of the sites where it was being developed.

"She got that vaccine in less than 40 hours and survived," said Geisbert, though it's impossible to know whether that was because of the vaccine. "She lived. That's all I care about."

With greater financial support, scientists said, Ebola treatments could be ready for use sooner. For less than $10 million, said Vanderbilt's Crowe, four or five of the experimental drugs could be ready for testing within in four months.

All of them seem to be effective only in a small window after exposure, however.

"Nothing on planet Earth is going to work if somebody comes in with full-blown Ebola hemorrhagic fever and they are 24 hours or 72 hours from death," said Geisbert. "The damage has been done."

You May Like

FIFA Indictments Put Gold Cup Tournament Under Cloud

Experts say US indictments could lead to charges of other world soccer officials, and lead to major shakeup in sport's governance More

Video Seoul Sponsors Korean Unification Fair

At a recent even in Seoul, border communities promoted benefits of increased cooperation and North Korean defectors shared stories of life since the war More

Video VOA EXCLUSIVE: Iraq President Vows to Fight IS 'Until They Are Killed or We Die'

In wide-ranging interview with VOA Persian service reporter, Fuad Masum describes conflict as new type of fight that will take time to win More

This forum has been closed.
Comment Sorting
Comments
     
by: John
August 11, 2014 11:00 AM
The US is still involved in the war in Somalia, decades after Bush Snr foolishly sent troops to help distribute food to the starving. The revolt by Boko Haram against polio vaccination goes from strength to strength. (Don't know whether the suit against the drug company that tested an experimental drug on the people of Kano has been settled though.) Yet some people still think we should give experimental drugs to Africans. They'll never learn!! The fact is, if Africans were really concerned about this disease, they'd have made a deal with Western drug companies to do the clinical trials of potential vaccines and cures decades ago. This doesn't take super technical skill; merely careful record keeping and a plentiful supply of victims---oops brave volunteers, to try the drugs. They just decided to wait until we panicked, so we'd provide all the money and guinea pigs ourselves. Must admit their strategy is working like a charm!!!

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Expelled from Pakistan, Afghan Refugees Return to Increased Hardshipi
X
Ayesha Tanzeem
May 28, 2015 6:48 PM
Undocumented refugees returning to Afghanistan from Pakistan have no jobs, no support system, and no home return to, and international aid agencies say they and the government are overwhelmed and under-resourced. Ayesha Tanzeem has more from Kabul.
Video

Video Expelled from Pakistan, Afghan Refugees Return to Increased Hardship

Undocumented refugees returning to Afghanistan from Pakistan have no jobs, no support system, and no home return to, and international aid agencies say they and the government are overwhelmed and under-resourced. Ayesha Tanzeem has more from Kabul.
Video

Video Britain Makes Controversial Move to Crack Down on Extremism

Britain is moving to tighten controls on extremist rhetoric, even when it does not incite violence or hatred -- a move that some are concerned might unduly restrict basic freedoms. It is an issue many countries are grappling with as extremist groups gain power in the Middle East, fueled in part by donations and fighters from the West. VOA’s Al Pessin reports from London.
Video

Video Floodwaters Recede in Houston, but Rain Continues

Many parts of Texas are recovering from one of the worst natural disasters to hit the southwestern state. Heavy rains on Monday and early Tuesday caused rivers to swell in eastern and central Texas, washing away homes and killing at least 13 people. As VOA’s Greg Flakus reports from Houston, floodwaters are receding slowly in the country's fourth-largest city, and there likely is to be more rain in the coming days.
Video

Video 3D Printer Makes Replica of Iconic Sports Car

Cars with parts made by 3D printers are already on the road, but engineers are still learning about this new technology. While testing the possibility of printing an entire car, researchers at the U.S. Department of Energy recently created an electric-powered replica of an iconic sports roadster. VOA’s George Putic has more.
Video

Video Al-Shabab Recruitment Drive Still on In Kenya

The al-Shabab militants that have long battled for control of Somalia also have recruited thousands of young people in Kenya, leaving many families disconsolate. Mohammed Yusuf recently visited the Kenyan town of Isiolo, and met with relatives of those recruited, as well as a many who have helped with the recruiting.
Video

Video US Voters Seek Answers From Presidential Candidates on IS Gains

The growth of the Islamic State militant group in Iraq and Syria comes as the 2016 U.S. presidential campaign kicks off in the Midwest state of Iowa.   As VOA’s Kane Farabaugh reports, voters want to know how the candidates would handle recent militant gains in the Middle East.
Video

Video A Small Oasis on Kabul's Outskirts Provides Relief From Security Tensions

When people in Kabul want to get away from the city and relax, many choose Qargha Lake, a small resort on the outskirts of Kabul. Ayesha Tanzeem visited and talked with people about the precious oasis.
Video

Video Film Festival Looks at Indigenous Peoples, Culture Conflict

A recent Los Angeles film festival highlighted the plight of people caught between two cultures. Mike O'Sullivan has more on the the Garifuna International Film Festival, a Los Angeles forum created by a woman from Central America who wants the world to know more about her culture.
Video

Video Kenyans Lament Losing Sons to al-Shabab

There is agony, fear and lost hope in the Kenyan town of Isiolo, a key target of a new al-Shabab recruitment drive. VOA's Mohammed Yusuf visits Isiolo to speak with families and at least one man who says he was a recruiter.
Video

Video Scientists Say Plankton More Important Than Previously Thought

Tiny ocean creatures called plankton are mostly thought of as food for whales and other large marine animals, but a four-year global study discovered, among other things, that plankton are a major source of oxygen on our planet. VOA’s George Putic reports.
Video

Video Kenya’s Capital Sees Rise in Shisha Parlors

In Kenya, the smoking of shisha, a type of flavored tobacco, is the latest craze. Patrons are flocking to shisha parlors to smoke and socialize. But the practice can be addictive and harmful, though many dabblers may not realize the dangers, according to a new review. Lenny Ruvaga has more on the story for VOA from Nairobi, Kenya.
Video

Video Iowa Family's Sacrifice Shaped US Military Service for Generations

Few places in America have experienced war like Waterloo. This small town in the Midwest state of Iowa became famous during World War II not for what it accomplished, but what it lost. As VOA’s Kane Farabaugh reports, the legacy of one family’s sacrifice is still a reminder today of the real cost of war for all families on the homefront.

VOA Blogs